Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States.
| Revenue (Most Recent Fiscal Year) | $57.80M |
| Net Income (Most Recent Fiscal Year) | $-97.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.40 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -77.72% |
| Net Margin (Trailing 12 Months) | -77.48% |
| Return on Equity (Trailing 12 Months) | -293.05% |
| Return on Assets (Trailing 12 Months) | -63.85% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.05 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.05 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.06 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.08 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.49 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.29 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 301.71M |
| Free Float | 289.34M |
| Market Capitalization | $162.44M |
| Average Volume (Last 20 Days) | 6.07M |
| Beta (Past 60 Months) | 1.18 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 56.93% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |